



Estados Clínicos



Adaptado de Scher e Heller, *Urology* 2000



Estudios de Fase 3

CHAARTED¹: **ChemoHormonal** Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer.

STAMPEDE^{2,3}: Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy: a multi-stage multi-arm randomised controlled trial.

LATITUDE⁴: A phase 3, double-blind, randomized trial of androgen deprivation therapy with **abiraterone** acetate plus prednisone or placebo in newly diagnosed high-risk metastatic hormone-naïve prostate cancer patients.

ARCHES⁵: Phase 3 study of androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer.

ENZAMET⁶: A randomized, phase III trial evaluating the impact of adding **enzalutamide** to standard initial treatment for metastatic hormone-sensitive prostate cancer.

TITAN⁷: phase III double-blind, randomized study of **apalutamide** versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.


ARASENS: A phase 3 trial of **darolutamide** in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer. Ongoing trial; results pending.

1. N Engl J Med. 2015 Aug 20;373(8):737-46. 2. Lancet 2016 Mar 19;387(10024):1163-77. 3. N Engl J Med. 2017 Jul 27;377(4):338-351. 4. N Engl J Med. 2017 Jul 27;377(4):352-360. 5. J Clin Oncol. 2019 Nov 10;37(32):2974-2986. 6. N Engl J Med. 2019 Jul 11;381(2):121-131. 7. N Engl J Med. 2019 Jul 4;381(1):13-24

Opções pós Docetaxel



	Agente	Mecanismo	Comparador	HR	Δ Sobrevida (mes)	P
2010	Sipuleucel - T	Vacina	Placebo	0.78	4.1	0.03
2010	Cabazitaxel	taxano	Mitoxantrona	0.72	2.4	<.0001
2011	Abiraterona	CYP 17	Prednisona	0.74	4.6	<.0001
2012	Enzalutamida	AR	placebo	0.63	4.8	<.001
2013	Radium-223	Emissão α	placebo	0.70	3.6	<.001
2021	Lu-177-PSMA	Emissão β	Rx padrão	0.62	4	<.001





Obrigado

oren.smaletz@einstein.br